$SXTP
60 DEGREES PHARMACEUTICALS, INC. Stock $sxtp

$sxtp Overview Financials Valuation SEC Filings Company Website

2024 Q4 Form 10-Q Financial Statement

#000121390024098195 Filed on November 14, 2024

Income Statement

Concept	2024 Q4	2024 Q3
Revenue		$135.3K
YoY Change		164.31%
Cost Of Revenue		$111.7K
YoY Change		56.87%
Gross Profit		$23.61K
YoY Change		-217.98%
Gross Profit Margin		17.45%
Selling, General & Admin		$1.215M
YoY Change		-7.5%
% of Gross Profit		5147.21%
Research & Development		$940.1K
YoY Change		256.49%
% of Gross Profit		3982.31%
Depreciation & Amortization		$4.334K
YoY Change		-20.98%
% of Gross Profit		18.36%
Operating Expenses		$2.155M
YoY Change		36.63%
Operating Profit		-$2.119M
YoY Change		39.23%
Interest Expense		-$41.56K
YoY Change		-203.62%
% of Operating Profit
Other Income/Expense, Net		$16.62K
YoY Change		-123.58%
Pretax Income		-$2.160M
YoY Change		-151.76%
Income Tax		$250.00
% Of Pretax Income
Net Earnings		-$2.160M
YoY Change		-151.63%
Net Earnings / Revenue		-1596.38%
Basic Earnings Per Share		-$0.93
Diluted Earnings Per Share		-$0.93
COMMON SHARES
Basic Shares Outstanding	2.297M shares	1.768M shares
Diluted Shares Outstanding		2.443M shares

Balance Sheet

Concept	2024 Q4	2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments		$5.012M
YoY Change		125.92%
Cash & Equivalents		$3.301M
Short-Term Investments		$1.712M
Other Short-Term Assets		$1.103M
YoY Change		-81.43%
Inventory		$452.0K
Prepaid Expenses
Receivables		$323.8K
Other Receivables		$0.00
Total Short-Term Assets		$6.891M
YoY Change		-22.53%
LONG-TERM ASSETS
Property, Plant & Equipment		$155.3K
YoY Change		3947.37%
Goodwill
YoY Change
Intangibles		$264.4K
YoY Change		17.46%
Long-Term Investments
YoY Change
Other Assets		$374.6K
YoY Change
Total Long-Term Assets		$529.9K
YoY Change		107.47%
TOTAL ASSETS
Total Short-Term Assets		$6.891M
Total Long-Term Assets		$529.9K
Total Assets		$7.421M
YoY Change		-18.9%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable		$677.6K
YoY Change		149.49%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt		$0.00
YoY Change
Long-Term Debt Due		$8.772K
YoY Change		0.02%
Total Short-Term Liabilities		$1.310M
YoY Change		-47.2%
LONG-TERM LIABILITIES
Long-Term Debt		$147.9K
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities		$147.9K
YoY Change		-3.08%
TOTAL LIABILITIES
Total Short-Term Liabilities		$1.310M
Total Long-Term Liabilities		$147.9K
Total Liabilities		$1.458M
YoY Change		-44.64%
SHAREHOLDERS EQUITY
Retained Earnings		-$38.48M
YoY Change		25.89%
Common Stock		$186.00
YoY Change		-67.93%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity		$6.040M
YoY Change
Total Liabilities & Shareholders Equity		$7.421M
YoY Change		-18.9%

Cashflow Statement

Concept	2024 Q4	2024 Q3
OPERATING ACTIVITIES
Net Income		-$2.160M
YoY Change		-151.63%
Depreciation, Depletion And Amortization		$4.334K
YoY Change		-20.98%
Cash From Operating Activities		-$1.681M
YoY Change		-55.2%
INVESTING ACTIVITIES
Capital Expenditures		$38.65K
YoY Change		38.48%
Acquisitions
YoY Change
Other Investing Activities		-$1.708M
YoY Change
Cash From Investing Activities		-$1.747M
YoY Change		6158.15%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		5.150M
YoY Change		-13.75%
NET CHANGE
Cash From Operating Activities		-1.681M
Cash From Investing Activities		-1.747M
Cash From Financing Activities		5.150M
Net Change In Cash		1.722M
YoY Change		-21.36%
FREE CASH FLOW
Cash From Operating Activities		-$1.681M
Capital Expenditures		$38.65K
Free Cash Flow		-$1.720M
YoY Change		-54.51%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2024Q3	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1		usd
	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1		usd
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1861914	shares
CY2024Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1861914	shares
CY2024Q3	us-gaap	Common Stock Value CommonStockValue	186	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	48	usd
CY2024Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	34815642	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	27457335	usd
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	9.13
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent		usd
CY2023Q3	us-gaap	Gain Loss On Derivative Instruments Held For Trading Purposes Net GainLossOnDerivativeInstrumentsHeldForTradingPurposesNet		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2024-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-41719
	dei	Entity Registrant Name EntityRegistrantName	60 DEGREES PHARMACEUTICALS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	45-2406880
	dei	Entity Address Address Line1 EntityAddressAddressLine1	1025 Connecticut Avenue
	dei	Entity Address Address Line2 EntityAddressAddressLine2	NW Suite 1000
	dei	Entity Address City Or Town EntityAddressCityOrTown	Washington, D.C.
	dei	Entity Address State Or Province EntityAddressStateOrProvince	WA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	20036
	dei	City Area Code CityAreaCode	(202)
	dei	Local Phone Number LocalPhoneNumber	327-5422
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	2297465	shares
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3300688	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2142485	usd
CY2024Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	323822	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	231332	usd
CY2024Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1102948	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4402602	usd
CY2024Q3	us-gaap	Short Term Investments ShortTermInvestments	1711497	usd
CY2024Q3	us-gaap	Inventory Net InventoryNet	452036	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	466169	usd
CY2024Q3	us-gaap	Assets Current AssetsCurrent	6890991	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	7242588	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	155257	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	57761	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	13517	usd
CY2024Q3	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	110294	usd
CY2023Q4	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	242647	usd
CY2024Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	264351	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	227258	usd
CY2024Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	374645	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	483422	usd
CY2024Q3	us-gaap	Assets Assets	7420893	usd
CY2023Q4	us-gaap	Assets Assets	7783771	usd
CY2024Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	677617	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	506206	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	13650	usd
CY2024Q3	sxtp	Sbaeid Lincluding Accrued Interest Current SBAEIDLincludingAccruedInterestCurrent	8772	usd
CY2023Q4	sxtp	Sbaeid Lincluding Accrued Interest Current SBAEIDLincludingAccruedInterestCurrent	8772	usd
CY2024Q3	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	623762	usd
CY2023Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	2306796	usd
CY2024Q3	us-gaap	Liabilities Current LiabilitiesCurrent	1310151	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2835424	usd
CY2024Q3	sxtp	Sbaeid Lincluding Accrued Interest Non Current SBAEIDLincludingAccruedInterestNonCurrent	147895	usd
CY2023Q4	sxtp	Sbaeid Lincluding Accrued Interest Non Current SBAEIDLincludingAccruedInterestNonCurrent	150251	usd
CY2024Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	147895	usd
CY2023Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	150251	usd
CY2024Q3	us-gaap	Liabilities Liabilities	1458046	usd
CY2023Q4	us-gaap	Liabilities Liabilities	2985675	usd
CY2024Q3	us-gaap	Preferred Stock Value PreferredStockValue	9567439	usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	9858040	usd
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	484187	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	484187	shares
CY2024Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	139207	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	135561	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-38482920	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-32580850	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	6039554	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	4870134	usd
CY2024Q3	us-gaap	Minority Interest MinorityInterest	-76707	usd
CY2023Q4	us-gaap	Minority Interest MinorityInterest	-72038	usd
CY2024Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	5962847	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	4798096	usd
CY2024Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	7420893	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	7783771	usd
CY2024Q3	us-gaap	Revenues Revenues	135293	usd
CY2023Q3	us-gaap	Revenues Revenues	51188	usd
	us-gaap	Revenues Revenues	376728	usd
	us-gaap	Revenues Revenues	127892	usd
CY2024Q3	us-gaap	Cost Of Revenue CostOfRevenue	111687	usd
CY2023Q3	us-gaap	Cost Of Revenue CostOfRevenue	71196	usd
	us-gaap	Cost Of Revenue CostOfRevenue	266688	usd
	us-gaap	Cost Of Revenue CostOfRevenue	328293	usd
CY2024Q3	us-gaap	Gross Profit GrossProfit	23606	usd
CY2023Q3	us-gaap	Gross Profit GrossProfit	-20008	usd
	us-gaap	Gross Profit GrossProfit	110040	usd
	us-gaap	Gross Profit GrossProfit	-200401	usd
CY2024Q3	us-gaap	Revenue Not From Contract With Customer Other RevenueNotFromContractWithCustomerOther	12818	usd
CY2023Q3	us-gaap	Revenue Not From Contract With Customer Other RevenueNotFromContractWithCustomerOther	75566	usd
	us-gaap	Revenue Not From Contract With Customer Other RevenueNotFromContractWithCustomerOther	43177	usd
	us-gaap	Revenue Not From Contract With Customer Other RevenueNotFromContractWithCustomerOther	82974	usd
CY2024Q3	sxtp	Net Revenue Loss NetRevenueLoss	36424	usd
CY2023Q3	sxtp	Net Revenue Loss NetRevenueLoss	55558	usd
	sxtp	Net Revenue Loss NetRevenueLoss	153217	usd
	sxtp	Net Revenue Loss NetRevenueLoss	-117427	usd
CY2024Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	940063	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	263703	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4372571	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	591569	usd
CY2024Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1215053	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1313617	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3419747	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2551426	usd
CY2024Q3	us-gaap	Operating Expenses OperatingExpenses	2155116	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	1577320	usd
	us-gaap	Operating Expenses OperatingExpenses	7792318	usd
	us-gaap	Operating Expenses OperatingExpenses	3142995	usd
CY2024Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-2118692	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-1521762	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-7639101	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-3260422	usd
CY2024Q3	us-gaap	Interest Expense Other InterestExpenseOther	1467	usd
CY2023Q3	us-gaap	Interest Expense Other InterestExpenseOther	40106	usd
	us-gaap	Interest Expense Other InterestExpenseOther	6490	usd
	us-gaap	Interest Expense Other InterestExpenseOther	2281191	usd
	us-gaap	Gain Loss On Derivative Instruments Held For Trading Purposes Net GainLossOnDerivativeInstrumentsHeldForTradingPurposesNet	-399725	usd
CY2024Q3	us-gaap	Gain Loss On Sale Of Derivatives GainLossOnSaleOfDerivatives	-56712	usd
CY2023Q3	us-gaap	Gain Loss On Sale Of Derivatives GainLossOnSaleOfDerivatives	92490	usd
	us-gaap	Gain Loss On Sale Of Derivatives GainLossOnSaleOfDerivatives	1683034	usd
	us-gaap	Gain Loss On Sale Of Derivatives GainLossOnSaleOfDerivatives	95324	usd
CY2023Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-391593	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-1231480	usd
CY2023Q3	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	6105066	usd
	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	5379269	usd
CY2024Q3	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	16623	usd
CY2023Q3	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-70490	usd
	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	56569	usd
	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-69169	usd
CY2024Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-41556	usd
CY2023Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	5695367	usd
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	1733113	usd
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	1493028	usd
CY2024Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2160248	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	4173605	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5905988	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1767394	usd
CY2024Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	250	usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	63	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	751	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	189	usd
CY2024Q3	us-gaap	Profit Loss ProfitLoss	-2160498	usd
CY2023Q3	us-gaap	Profit Loss ProfitLoss	4173542	usd
	us-gaap	Profit Loss ProfitLoss	-5906739	usd
	us-gaap	Profit Loss ProfitLoss	-1767583	usd
CY2024Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-713	usd
CY2023Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-9656	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-4669	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-14165	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-2159785	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	4183198	usd
	us-gaap	Net Income Loss NetIncomeLoss	-5902070	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1753418	usd
CY2024Q3	us-gaap	Profit Loss ProfitLoss	-2160498	usd
CY2023Q3	us-gaap	Profit Loss ProfitLoss	4173542	usd
	us-gaap	Profit Loss ProfitLoss	-5906739	usd
	us-gaap	Profit Loss ProfitLoss	-1767583	usd
CY2024Q3	us-gaap	Foreign Currency Transaction Gain Loss Unrealized After Tax ForeignCurrencyTransactionGainLossUnrealizedAfterTax	4403	usd
CY2023Q3	us-gaap	Foreign Currency Transaction Gain Loss Unrealized After Tax ForeignCurrencyTransactionGainLossUnrealizedAfterTax	9342	usd
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized After Tax ForeignCurrencyTransactionGainLossUnrealizedAfterTax	3646	usd
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized After Tax ForeignCurrencyTransactionGainLossUnrealizedAfterTax	7678	usd
CY2024Q3	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-2156095	usd
CY2023Q3	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	4182884	usd
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-5903093	usd
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-1759905	usd
CY2024Q3	us-gaap	Net Income Loss Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossAttributableToNonredeemableNoncontrollingInterest	-713	usd
CY2023Q3	us-gaap	Net Income Loss Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossAttributableToNonredeemableNoncontrollingInterest	-9656	usd
	us-gaap	Net Income Loss Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossAttributableToNonredeemableNoncontrollingInterest	-4669	usd
	us-gaap	Net Income Loss Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossAttributableToNonredeemableNoncontrollingInterest	-14165	usd
CY2024Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2155382	usd
CY2023Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	4192540	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-5898424	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1745740	usd
CY2024Q3	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	116571	usd
CY2023Q3	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	101538	usd
	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	352333	usd
	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	101538	usd
CY2024Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2271953	usd
CY2023Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	4091002	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6250757	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1847278	usd
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.93
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.93
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	9.13
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-4.35
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.35
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-6.59
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-6.59
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2443198	shares
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2443198	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	448174	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	448174	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1437584	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1437584	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	280391	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	280391	shares
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	4798096	usd
CY2024Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1898296	usd
CY2024Q1	sxtp	Stock Issued During Period Value Stock Issuance Of Common Stock Upon Exercise Of Pre Funded Warrants StockIssuedDuringPeriodValueStockIssuanceOfCommonStockUponExerciseOfPreFundedWarrants	4995	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-3894	usd
CY2024Q1	us-gaap	Profit Loss ProfitLoss	427985	usd
CY2024Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	7125478	usd
CY2024Q2	sxtp	Stock Issued During Period Value Stock Issuance Of Common Stock Upon Exercise Of Pre Funded Warrants StockIssuedDuringPeriodValueStockIssuanceOfCommonStockUponExerciseOfPreFundedWarrants	4995	usd
CY2024Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	3137	usd
CY2024Q2	us-gaap	Profit Loss ProfitLoss	-4174226	usd
CY2024Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	2959384	usd
CY2024Q3	sxtp	Issuance Of Common Stock Net Of Offering Costs Paid IssuanceOfCommonStockNetOfOfferingCostsPaid	264774	usd
CY2024Q3	sxtp	Stock Issued During Period Value Issuance Of Common Stock Pursuant To Atm Offering Net Of Offering Costs StockIssuedDuringPeriodValueIssuanceOfCommonStockPursuantToATMOfferingNetOfOfferingCosts	1729810	usd
CY2024Q3	sxtp	Issuance Of Warrants In Private Placement Net Of Offering Costs Paid IssuanceOfWarrantsInPrivatePlacementNetOfOfferingCostsPaid	582600	usd
CY2024Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	3414502	usd
CY2024Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	15246	usd
CY2024Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	4403	usd
CY2024Q3	us-gaap	Profit Loss ProfitLoss	-2160498	usd
CY2024Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	5962847	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-24149060	usd
CY2023Q1	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	5378908	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1290	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-2597534	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-21368976	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-374	usd
CY2023Q2	us-gaap	Profit Loss ProfitLoss	-3343591	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-24712941	usd
CY2023Q3	sxtp	Stock Issued Period Value Issuance Of Common Stock For Payment Of Deferred Compensation StockIssuedPeriodValueIssuanceOfCommonStockForPaymentOfDeferredCompensation	155000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	7989598	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	10128500	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	838748	usd
CY2023Q3	sxtp	Issuance Of Common Stock Pursuant To Ipo Net Of Underwriting Discounts IssuanceOfCommonStockPursuantToIPONetOfUnderwritingDiscounts	1266740	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	6235276	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1131771	usd
CY2023Q3	sxtp	Stock Issued During Period Valu Sharebased Compensation Awards StockIssuedDuringPeriodValuSharebasedCompensationAwards	187200	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	271066	usd
CY2023Q3	sxtp	Prepaid Sharebased Compensation PrepaidSharebasedCompensation	109148	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	9342	usd
CY2023Q3	us-gaap	Profit Loss ProfitLoss	4173542	usd
CY2023Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	6516250	usd
	us-gaap	Profit Loss ProfitLoss	-5906739	usd
	us-gaap	Profit Loss ProfitLoss	-1767583	usd
	us-gaap	Depreciation Depreciation	6277	usd
	us-gaap	Depreciation Depreciation	19287	usd
	us-gaap	Adjustment For Amortization AdjustmentForAmortization	28004	usd
	us-gaap	Adjustment For Amortization AdjustmentForAmortization	20606	usd
	sxtp	Amortization Of Debt Discount AmortizationOfDebtDiscount	669148	usd
	us-gaap	Gain Loss On Sale Of Other Assets GainLossOnSaleOfOtherAssets	-13517	usd
	us-gaap	Gain Loss On Sale Of Other Assets GainLossOnSaleOfOtherAssets	-37035	usd
	sxtp	Amortization Of Note Issuance Costs AmortizationOfNoteIssuanceCosts	67728	usd
	sxtp	Amortization Of Capitalized Share Based Payments AmortizationOfCapitalizedShareBasedPayments	3531763	usd
	sxtp	Amortization Of Capitalized Share Based Payments AmortizationOfCapitalizedShareBasedPayments	690173	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	212605	usd
	sxtp	Share Based Compensation Under Equity Incentive Plan ShareBasedCompensationUnderEquityIncentivePlan	15246	usd
	sxtp	Share Based Compensation Under Equity Incentive Plan ShareBasedCompensationUnderEquityIncentivePlan	458266	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-1231480	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	1683034	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	95324	usd
	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	-399725	usd
	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	5379269	usd
	sxtp	Writeoffs Of Capitalized Patents WriteoffsOfCapitalizedPatents	11300	usd
	us-gaap	Inventory Lifo Reserve Period Charge InventoryLIFOReservePeriodCharge	-139946	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	92490	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	92044	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	99756	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1512578	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-14133	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-60205	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	171411	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-489337	usd
	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	5853	usd
	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	-1267703	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-13650	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-37122	usd
	us-gaap	Increase Decrease In Deferred Compensation IncreaseDecreaseInDeferredCompensation	-100000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4009871	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4479242	usd
	sxtp	Payment Of Capitalization Of Patents PaymentOfCapitalizationOfPatents	49869	usd
	sxtp	Payment Of Capitalization Of Patents PaymentOfCapitalizationOfPatents	29220	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	103773	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1823	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	25374	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	18283	usd
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	1708000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1887016	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-49326	usd
	sxtp	Net Proceeds From Shares And Warrants Offering NetProceedsFromSharesAndWarrantsOffering	1914513	usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	102077	usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	150420	usd
	sxtp	Net Of Underwriting Discounts And Commissions Paid NetOfUnderwritingDiscountsAndCommissionsPaid	1047692	usd
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	6454325	usd
	sxtp	Atm Offering Net Of Offering Costs Paid ATMOfferingNetOfOfferingCostsPaid	203914	usd
	sxtp	Proceeds From Issuance Atm Offering Costs ProceedsFromIssuanceATMOfferingCosts	1790670	usd
	sxtp	Private Placement Net Of Offering Costs PrivatePlacementNetOfOfferingCosts	557600	usd
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	3439502	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1131771	usd
	sxtp	Proceeds From Exercise Of Pre Funded Warrants ProceedsFromExerciseOfPreFundedWarrants	9990	usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	650000	usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	1611111	usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	250000	usd
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	250000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	7052598	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	6474565	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2492	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	7678	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	1158203	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	1953675	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2142485	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	264865	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3300688	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2218540	usd
	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	7989598	usd
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	10128500	usd
	sxtp	Conversion Of Series A Preferred Stock Into Common Stock ConversionOfSeriesAPreferredStockIntoCommonStock	290601	usd
	sxtp	Conversion Of Series A Preferred Stock Into Common Stock ConversionOfSeriesAPreferredStockIntoCommonStock	270460	usd
	sxtp	Capitalized Share Based Payments To Vendors CapitalizedShareBasedPaymentsToVendors	4916556	usd
	us-gaap	Notes Issued1 NotesIssued1	71364	usd
	us-gaap	Notes Issued1 NotesIssued1	301416	usd
	sxtp	Reclassification Of Liabilityclassified Warrants To Equityclassified ReclassificationOfLiabilityclassifiedWarrantsToEquityclassified	838748	usd
	sxtp	Additions To Rou Assets For Lease Renewal AdditionsToROUAssetsForLeaseRenewal	50922	usd
	sxtp	Additions To Lease Liabilities For Lease Renewal AdditionsToLeaseLiabilitiesForLeaseRenewal	50570	usd
	sxtp	Debt Discount Recorded In Connection With Derivative Liabilities DebtDiscountRecordedInConnectionWithDerivativeLiabilities	650000	usd
	us-gaap	Stock Issued1 StockIssued1	480000	usd
	us-gaap	Noncash Or Part Noncash Acquisition Intangible Assets Acquired1 NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1	33895	usd
	us-gaap	Nature Of Operations NatureOfOperations	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>1. NATURE OF OPERATIONS</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">60 Degrees Pharmaceuticals, Inc. was incorporated in Delaware on June 1, 2022 and merged on the same day with 60 Degrees Pharmaceuticals, LLC, a District of Columbia limited liability company organized on September 9, 2010. 60 Degrees Pharmaceuticals, Inc. and its subsidiary (referred to collectively as the “Company”, “60P”, or “60 Degrees Pharmaceuticals”) is a specialty pharmaceutical company that specializes in the development and marketing of new medicines for the treatment and prevention of infectious diseases. 60P achieved FDA approval of its lead product, ARAKODA<sup>®</sup> (tafenoquine), for malaria prevention, in 2018. Currently, 60P’s pipeline under development covers development programs for tick-borne fungal and other viral diseases utilizing three of the Company’s future products: (i) new products that contain the Arakoda regimen of tafenoquine; (ii) new products that contain tafenoquine; and (iii) celgosivir. The Company’s headquarters are located in Washington, D.C., with a majority-owned subsidiary in Australia.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">(a) Initial Public Offering</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 14, 2023, the Company closed its initial public offering consisting of 117,925 units at a price of $63.60 per unit for $6,454,325 in net proceeds, after deducting the underwriting discount and commission and other estimated offering expenses paid by the Company at closing (the “IPO”). Each unit consisted of one share of common stock, one tradeable warrant to purchase one share of common stock at an exercise price of $73.14 per share (a “Tradeable Warrant”), and one non-tradeable warrant to purchase one share of the Company’s common stock at an exercise price of $76.32 per share (a “Non-tradeable Warrant”). The Tradeable Warrants and Non-Tradeable Warrants were immediately exercisable on the date of issuance and will expire five years from the date of issuance (July 12, 2023 to July 12, 2028).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company granted the underwriters a 45-day over-allotment option to purchase up to 17,689 shares of the Company’s common stock at a price of $63.36 per share and/or 17,689 Tradeable Warrants at a price of $0.12 per Tradeable Warrant and/or 17,689 Non-tradeable Warrants at $0.12 per Non-tradeable Warrant, or any combination thereof (the “IPO Over-Allotment”). On July 13, 2023, the underwriters partially exercised the Over-Allotment and purchased an additional 8,387 Tradeable Warrants and 8,387 Non-tradeable Warrants. The Company also issued to the underwriters warrants to purchase 7,076 shares of the Company’s common stock, at an exercise price of $69.96 per share, equal to 110% of the offering price per unit (the “IPO Representative Warrants”). The IPO Representative Warrants are exercisable for a period of five years from the date of issuance (July 14, 2023 to July 14, 2028).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The units were offered and sold pursuant to the Company’s Registration Statement on Form S-1, as amended (File No. 333-269483), originally filed with the Securities and Exchange Commission (the “SEC”) on January 31, 2023 (the “IPO Registration Statement”) and the final prospectus filed with the SEC pursuant to Rule 424(b)(4) of the Securities Act of 1933, as amended. The Registration Statement was declared effective by the SEC on July 11, 2023. The common stock and tradeable warrants began trading on The Nasdaq Capital Market on July 12, 2023 under the symbols “SXTP” and “SXTPW,” respectively. The closing of the IPO occurred on July 14, 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">(b) Going Concern</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company’s financial statements are prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of obligations in the normal course of business. However, the Company has not demonstrated the ability to generate enough revenues to date to cover operating expenses and has accumulated losses to date. This condition, among others, raises substantial doubt about the ability of the Company to continue as a going concern for one year from the date these consolidated condensed financial statements are issued.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">In view of these matters, continuation as a going concern is dependent upon the Company’s ability to meet its financial requirements, raise additional capital, and achieve gross profitability from their single marketed product. The financial statements do not include any adjustments to the amount and classification of assets and liabilities that may be necessary should the Company not continue as a going concern.</span> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management plans to fund operations of the Company through third party and related party debt/advances, private placement of restricted securities and the issuance of stock in a subsequent offering until such a time as the business achieves profitability or a business combination may be achieved.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 30, 2024, the Company had cash and cash equivalents totaling $3,300,688, as compared to cash and cash equivalents totaling $2,142,485 at December 31, 2023. During the nine months ended September 30, 2024, the Company used $4,009,871 of cash in its operating activities.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company’s future results are subject to substantial risks and uncertainties. The Company has operated at a loss for its entire history and there can be no assurance that it will ever achieve or maintain profitability. The Company has historically funded its operations primarily with proceeds from sales of common stock and warrants for the purchase of common stock, proceeds from the issuance of convertible debt, and borrowings under loan and security agreements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company expects to need to raise additional capital under structures available to the Company, including debt and/or equity offerings, which may not be on favorable terms. The Company would not have sufficient funds to meet its obligations within twelve months from the issuance date of these consolidated condensed financial statements. As such, there is uncertainty regarding the Company’s ability to maintain liquidity sufficient to operate its business effectively, which raises substantial doubt about the Company’s ability to continue as a going concern. Debt financing and equity financing, if available, may involve agreements that include covenants limiting or restricting the Company’s ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If the Company raises funds through collaborations, or other similar arrangements with third parties, it may have to relinquish valuable rights to its technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to the Company and/or may reduce the value of its common stock. If the Company is unable to raise additional funds through equity or debt financings when needed, it may be required to delay, limit, reduce or terminate its product development or future commercialization efforts or grant rights to develop and market its product candidates even if the Company would otherwise prefer to develop and market such product candidates itself.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company also expects to use cash and cash equivalents to fund activities relating to commercial support for its existing product and any future clinical research trials and operating activities. The Company’s future liquidity and capital requirements will depend on numerous factors, including the initiation and progress of clinical trials and research and product development programs; obtaining regulatory approvals and complying with applicable laws and regulations; the timing and effectiveness of product commercialization activities, including marketing arrangements; the timing and costs involved in preparing, filing, prosecuting, defending and enforcing intellectual property rights; and the effect of competing technological and market developments.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company’s capital commitments over the next twelve months include interest obligations on the Company’s debt arrangements of $8,772 and $677,617 to satisfy current accounts payable and accrued expenses.</p>
CY2023Q3	sxtp	Percentage Of Offering Price Per Unit PercentageOfOfferingPricePerUnit	1.10	pure
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3300688	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2142485	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4009871	usd
CY2024Q3	sxtp	Sbaeid Lincluding Accrued Interest Current SBAEIDLincludingAccruedInterestCurrent	8772	usd
CY2024Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	677617	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">(c) Use of Estimates</span></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates, and those estimates may be material. Significant estimates include the reserve for inventory, and derivative liabilities.</p>
	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1:12
CY2024Q3	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2024Q3	us-gaap	Inventory Write Down InventoryWriteDown	1165	usd
CY2023Q3	us-gaap	Inventory Write Down InventoryWriteDown	0	usd
	us-gaap	Inventory Write Down InventoryWriteDown	18490	usd
	us-gaap	Inventory Write Down InventoryWriteDown	94977	usd
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">(k) Concentrations</span></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents, short-term investments, accounts receivable, inventory purchases, and borrowings.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Significant customers represent any customer whose business makes up 10% of receivables or revenues. At September 30, 2024, significant customers represented 97% of receivables (consisting of two customers and one significant customer at 97%). At December 31, 2023, significant customers represented 92% of receivables (consisting of three customers and two significant customers at 79% and 13%, respectively). For the three months ended September 30, 2024, 92% of total net revenues (consisting of two customers and one significant customer) were generated from significant customers. For the three months ended September 30, 2023, 100% of total net revenues (consisting of one significant customer) were generated by significant customers. For the nine months ended September 30, 2024, 94% of total net revenues (consisting of three customers and one significant customer) were generated from significant customers. For the nine months ended September 30, 2023, 100% of the revenues were generated by the Company from significant customers, consisting of two customers at 72% and 28%. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Currently, the Company has exclusive relationships with distributors in Australia and Europe. A failure to perform by any of our current distributors would create disruption for patients in those markets.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Since the Company first started working on tafenoquine all inventory has been acquired in a collaborative relationship from a sole vendor. Should the vendor cease to supply tafenoquine, it would take significant costs and efforts to rebuild the supply chain with a new sole vendor sourcing the active pharmaceutical ingredient (“API”).</p>
CY2024Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	940063	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	263703	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4372571	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	591569	usd
CY2024Q3	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	623762	usd
CY2023Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	2306796	usd
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">(r) Reclassifications</span></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain prior period interim amounts have been reclassified for consistency with the current period presentation. These reclassifications had no material effect on the consolidated condensed results of operations and comprehensive (loss) income, shareholders’ equity (deficit), or cash flows.</p>
CY2024Q3	us-gaap	Inventory Work In Process InventoryWorkInProcess	367587	usd
CY2023Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	278987	usd
CY2024Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	84449	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	187182	usd
CY2024Q3	us-gaap	Inventory Net InventoryNet	452036	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	466169	usd
CY2024Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	299241	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	205825	usd
CY2024Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	143984	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	148064	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	155257	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	57761	usd
CY2024Q3	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	55800	usd
CY2024Q3	us-gaap	Depreciation Depreciation	4334	usd
CY2023Q3	us-gaap	Depreciation Depreciation	5485	usd
	us-gaap	Depreciation Depreciation	6277	usd
	us-gaap	Depreciation Depreciation	19287	usd
CY2024Q3	us-gaap	Finite Lived Patents Gross FiniteLivedPatentsGross	225485	usd
CY2023Q4	us-gaap	Finite Lived Patents Gross FiniteLivedPatentsGross	185595	usd
CY2024Q3	sxtp	Finite Lived Website Development Costs Gross FiniteLivedWebsiteDevelopmentCostsGross	104622	usd
CY2023Q4	sxtp	Finite Lived Website Development Costs Gross FiniteLivedWebsiteDevelopmentCostsGross	79248	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	330107	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	264843	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	65756	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	37585	usd
CY2024Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	264351	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	227258	usd
CY2024Q3	sxtp	Capitalized Website Developmentrelated Costs CapitalizedWebsiteDevelopmentrelatedCosts	3299	usd
CY2023Q3	sxtp	Capitalized Website Developmentrelated Costs CapitalizedWebsiteDevelopmentrelatedCosts	12283	usd
	sxtp	Capitalized Website Developmentrelated Costs CapitalizedWebsiteDevelopmentrelatedCosts	25374	usd
	sxtp	Capitalized Website Developmentrelated Costs CapitalizedWebsiteDevelopmentrelatedCosts	52178	usd
CY2024Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	10325	usd
CY2023Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	7414	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	28004	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	20606	usd
CY2024Q3	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	2922	usd
CY2023Q3	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	usd
	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	11300	usd
	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	usd
	sxtp	Capitalized Patent Expenses CapitalizedPatentExpenses	128722	usd
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1861914	shares
CY2024Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1861914	shares
CY2024Q3	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1:12
CY2024Q3	us-gaap	Stock Issued During Period Shares Acquisitions StockIssuedDuringPeriodSharesAcquisitions	93563	shares
CY2023Q3	us-gaap	Stock Issued During Period Shares Restricted Stock Award Gross StockIssuedDuringPeriodSharesRestrictedStockAwardGross	3336	shares
CY2023Q3	us-gaap	Stock Issued During Period Shares Conversion Of Convertible Securities StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities	142270	shares
CY2024Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	5.082
CY2024Q1	sxtp	Percentage Of Offering Price Per Unit PercentageOfOfferingPricePerUnit	1.10	pure
CY2024Q1	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P5Y
CY2024Q1	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	0.12
CY2024Q1	sxtp	Pre Funded Warrants Per Price PreFundedWarrantsPerPrice	0.12
	sxtp	Pre Funded Warrant PreFundedWarrant	12489	shares
	sxtp	Percentage Of Warrant Units Sold PercentageOfWarrantUnitsSold	0.15	pure
	sxtp	Percentage Of Warrant Underlying The Pre Funded Units Sold PercentageOfWarrantUnderlyingThePreFundedUnitsSold	0.15	pure
	sxtp	Percentage Of Pre Funded Warrant Underlying The Pre Funded Unit Sold PercentageOfPreFundedWarrantUnderlyingThePreFundedUnitSold	0.15	pure
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized	5	shares
CY2024Q1	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	4.5
CY2024Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	5	shares
CY2024Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.12
	sxtp	Percentage Of Offering Price Per Unit PercentageOfOfferingPricePerUnit	1.10	pure
	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	1900000	usd
CY2024Q1	sxtp	Pre Funded Warrants PreFundedWarrants	9990	shares
CY2024Q2	sxtp	Agreed To Return Shares AgreedToReturnShares	10000	shares
CY2024Q3	sxtp	Common Stock Aggregate Offering Price CommonStockAggregateOfferingPrice	1253603	usd
CY2024Q3	us-gaap	Deferred Offering Costs DeferredOfferingCosts	1774640	usd
CY2024Q3	us-gaap	Deferred Offering Costs DeferredOfferingCosts	1890705	usd
CY2024Q3	us-gaap	Deferred Offering Costs DeferredOfferingCosts	2190416	usd
CY2024Q3	us-gaap	Deferred Offering Costs DeferredOfferingCosts	2295192	usd
CY2024Q3	sxtp	Atm Offering Shares ATMOfferingShares	677819	shares
CY2024Q3	us-gaap	Proceeds From Other Equity ProceedsFromOtherEquity	1994583	usd
	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	12669	shares
	us-gaap	Warrant Exercise Price Increase WarrantExercisePriceIncrease	69.96
CY2024Q3	sxtp	Ipo Price Percentage IPOPricePercentage	1.10	pure
CY2024Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.379
CY2024Q3	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	3414502	usd
	us-gaap	Warrant Exercise Price Decrease WarrantExercisePriceDecrease	0.001
CY2024Q3	sxtp	Class Of Warrant Or Rightissued ClassOfWarrantOrRightissued	217391	shares
CY2024Q3	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P5Y
	sxtp	Pre Funded Warrants PreFundedWarrants	2898551	shares
	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	1131771	usd
	sxtp	Non Tradeable Warrants NonTradeableWarrants	7750	shares
	us-gaap	Warrant Exercise Price Decrease WarrantExercisePriceDecrease	73.14
	sxtp	Aggregate Cash Proceeds AggregateCashProceeds	9990	usd
CY2024Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	83259	shares
CY2024Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.12
	us-gaap	Preferred Stock Dividend Rate Percentage PreferredStockDividendRatePercentage	0.06	pure
	us-gaap	Dividends Preferred Stock DividendsPreferredStock	573046	usd
CY2024Q3	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	0	usd
CY2023Q3	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	3869	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	0	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	52628	usd
CY2024Q3	us-gaap	Interest Expense Debt InterestExpenseDebt	0	usd
CY2023Q3	us-gaap	Interest Expense Debt InterestExpenseDebt	4944	usd
	us-gaap	Interest Expense Debt InterestExpenseDebt	0	usd
	us-gaap	Interest Expense Debt InterestExpenseDebt	66558	usd
CY2022Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	17912	usd
CY2022Q1	us-gaap	Extinguishment Of Debt Amount ExtinguishmentOfDebtAmount	223077	usd
	sxtp	Vested Warrants VestedWarrants	P5Y
	us-gaap	Extinguishment Of Debt Amount ExtinguishmentOfDebtAmount	614670	usd
	us-gaap	Conversion Of Stock Shares Converted1 ConversionOfStockSharesConverted1	6661	shares
	us-gaap	Debt Conversion Original Debt Interest Rate Of Debt DebtConversionOriginalDebtInterestRateOfDebt	0.80	pure
	sxtp	Initial Public Offering Discount Percentages InitialPublicOfferingDiscountPercentages	0.15	pure
	sxtp	Common Stock Outstanding Percentages CommonStockOutstandingPercentages	0.199	pure
	us-gaap	Payments For Fees PaymentsForFees	10000000	usd
	us-gaap	Management Fee Expense ManagementFeeExpense	30000	usd
CY2024Q3	sxtp	Cumulative Dividend Percentage CumulativeDividendPercentage	0.06	pure
CY2024Q3	sxtp	Common Stock Ownership Percentage CommonStockOwnershipPercentage	0.199	pure
	sxtp	Equal Royalty Pay To Lender Percentage EqualRoyaltyPayToLenderPercentage	3.5	usd
CY2023Q1	us-gaap	Extinguishment Of Debt Amount ExtinguishmentOfDebtAmount	839887	usd
CY2023Q1	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis With Unobservable Inputs FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs	21520650	usd
CY2023Q1	sxtp	Fair Value Measurementwith Unobservable Inputs Reconciliation Recurring Basis Mark To Market Adjustment FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisMarkToMarketAdjustment	-339052	usd
CY2023Q1	sxtp	Fair Value Measurementwith Unobservable Inputs Reconciliation Recurring Basis Accrued Interest Recognized FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisAccruedInterestRecognized	634243	usd
CY2023Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	21815841	usd
CY2023Q2	sxtp	Fair Value Measurementwith Unobservable Inputs Reconciliation Recurring Basis Mark To Market Adjustment FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisMarkToMarketAdjustment	1064849	usd
CY2023Q2	sxtp	Fair Value Measurementwith Unobservable Inputs Reconciliation Recurring Basis Accrued Interest Recognized FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisAccruedInterestRecognized	659306	usd
CY2023Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	23539996	usd
CY2023Q3	sxtp	Fair Value Measurementwith Unobservable Inputs Reconciliation Recurring Basis Mark To Market Adjustment FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisMarkToMarketAdjustment	-6105066	usd
CY2023Q3	sxtp	Fair Value Net Derivative Asset Liability Measured On Recurring Basis With Unobservable Inputs Estinguishmentof Debt FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputsEstinguishmentofDebt	-17434930	usd
CY2022Q1	us-gaap	Conversion Of Stock Shares Converted1 ConversionOfStockSharesConverted1	92362	shares
	sxtp	Fair Value Measurementwith Unobservable Inputs Reconciliation Recurring Basis Mark To Market Adjustment FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisMarkToMarketAdjustment	6105066	usd
CY2019Q2	us-gaap	Debt Current DebtCurrent	3000000	usd
CY2019Q2	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	2100000	usd
CY2024Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	8772	usd
CY2024Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	147895	usd
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	8772	usd
CY2023Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	150251	usd
CY2024Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	683	usd
CY2024Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	3228	usd
CY2024Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	3342	usd
CY2024Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	142747	usd
CY2024Q3	us-gaap	Long Term Debt LongTermDebt	150000	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	1683034	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	95324	usd
CY2024Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	250	usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	63	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	751	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	189	usd
CY2024Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	668974	usd
CY2023Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	549031	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3547009	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1361044	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Outstanding Stock Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum	0.04	pure
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	416667	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.76
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	41.04
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	57
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	64183	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	20834	shares
CY2023Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	0	shares
CY2024Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	2438	shares
CY2024Q3	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	176471	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	948581	usd
CY2024Q3	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	110294	usd
CY2023Q4	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	242647	usd
CY2024Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	4938	usd
CY2023Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	13859	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	24067	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	41225	usd
CY2024Q3	sxtp	Number Of Non Audit Committee Chairs NumberOfNonAuditCommitteeChairs	2	pure
CY2015Q3	sxtp	Licensed Technology Term LicensedTechnologyTerm	P20Y
CY2015Q3	sxtp	Annual Royalty Payment Percentage AnnualRoyaltyPaymentPercentage	0.05	pure
CY2015Q3	us-gaap	Sales Commissions And Fees SalesCommissionsAndFees	75000	usd
CY2015Q3	us-gaap	Gain Loss On Sales Of Loans Net GainLossOnSalesOfLoansNet	6000000	usd
CY2024Q4	sxtp	Additional Shares Of Common Stock AdditionalSharesOfCommonStock	229000	shares
	sxtp	Common Stock Exercise Shares CommonStockExerciseShares	229000	shares
CY2024Q3	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q3	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q3	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q3	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q4	us-gaap	Short Term Investments ShortTermInvestments		usd
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset		usd
CY2024Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q3	us-gaap	Gain Loss On Derivative Instruments Held For Trading Purposes Net GainLossOnDerivativeInstrumentsHeldForTradingPurposesNet		usd
	us-gaap	Gain Loss On Derivative Instruments Held For Trading Purposes Net GainLossOnDerivativeInstrumentsHeldForTradingPurposesNet		usd
CY2024Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross		usd
CY2024Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross		usd
CY2024Q2	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther		usd
CY2024Q3	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1		usd
CY2024Q3	us-gaap	Adjustments To Additional Paid In Capital Stock Split AdjustmentsToAdditionalPaidInCapitalStockSplit		usd
CY2023Q1	us-gaap	Stock Issued During Period Value Share Based Compensation Forfeited StockIssuedDuringPeriodValueShareBasedCompensationForfeited		usd
CY2023Q3	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1		usd
CY2023Q3	sxtp	Contribution From Noncontrolling Interest ContributionFromNoncontrollingInterest		usd
	sxtp	Amortization Of Debt Discount AmortizationOfDebtDiscount		usd
	sxtp	Amortization Of Note Issuance Costs AmortizationOfNoteIssuanceCosts		usd
	us-gaap	Share Based Compensation ShareBasedCompensation		usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax		usd
	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1		usd
	sxtp	Writeoffs Of Capitalized Patents WriteoffsOfCapitalizedPatents		usd
	us-gaap	Inventory Lifo Reserve Period Charge InventoryLIFOReservePeriodCharge		usd
	us-gaap	Increase Decrease In Deferred Compensation IncreaseDecreaseInDeferredCompensation		usd
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments		usd
	sxtp	Net Proceeds From Shares And Warrants Offering NetProceedsFromSharesAndWarrantsOffering		usd
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering		usd
	sxtp	Proceeds From Issuance Atm Offering Costs ProceedsFromIssuanceATMOfferingCosts		usd
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement		usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
	sxtp	Proceeds From Exercise Of Pre Funded Warrants ProceedsFromExerciseOfPreFundedWarrants		usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable		usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable		usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt		usd
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt		usd
	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1		usd
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1		usd
	sxtp	Capitalized Share Based Payments To Vendors CapitalizedShareBasedPaymentsToVendors		usd
	sxtp	Reclassification Of Liabilityclassified Warrants To Equityclassified ReclassificationOfLiabilityclassifiedWarrantsToEquityclassified		usd
	sxtp	Additions To Rou Assets For Lease Renewal AdditionsToROUAssetsForLeaseRenewal		usd
	sxtp	Additions To Lease Liabilities For Lease Renewal AdditionsToLeaseLiabilitiesForLeaseRenewal		usd
	sxtp	Debt Discount Recorded In Connection With Derivative Liabilities DebtDiscountRecordedInConnectionWithDerivativeLiabilities		usd
	us-gaap	Stock Issued1 StockIssued1		usd
	us-gaap	Noncash Or Part Noncash Acquisition Intangible Assets Acquired1 NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1		usd
CY2022Q4	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis With Unobservable Inputs FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs		usd
CY2023Q3	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue		usd
CY2024Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear		usd
CY2024Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths		usd
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Central Index Key EntityCentralIndexKey	0001946563

Files In Submission

Name	View Source	Status
0001213900-24-098195-index-headers.html	Edgar Link	pending
0001213900-24-098195-index.html	Edgar Link	pending
0001213900-24-098195.txt	Edgar Link	pending
0001213900-24-098195-xbrl.zip	Edgar Link	pending
ea0220817-10q_60degrees.htm	Edgar Link	pending
ea022081701ex31-1_60degrees.htm	Edgar Link	pending
ea022081701ex31-2_60degrees.htm	Edgar Link	pending
ea022081701ex32-1_60degrees.htm	Edgar Link	pending
ea022081701ex32-2_60degrees.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
ea0220817-10q_60degrees_htm.xml	Edgar Link	completed
FilingSummary.xml	Edgar Link	unprocessable
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
sxtp-20240930.xsd	Edgar Link	pending
sxtp-20240930_cal.xml	Edgar Link	unprocessable
sxtp-20240930_lab.xml	Edgar Link	unprocessable
sxtp-20240930_pre.xml	Edgar Link	unprocessable
sxtp-20240930_def.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SXTP
60 DEGREES PHARMACEUTICALS, INC. Stock $sxtp

2024 Q4 Form 10-Q Financial Statement

#000121390024098195 Filed on November 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SXTP 60 DEGREES PHARMACEUTICALS, INC. Stock $sxtp

2024 Q4 Form 10-Q Financial Statement

#000121390024098195 Filed on November 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SXTP
60 DEGREES PHARMACEUTICALS, INC. Stock $sxtp